Business
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by differentiated clinical data and growing real-world confidence - New TTR amyloid depleter antibody program announced to explore the potential of ATTR-CM disease reve
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"BridgeBio Pharma, Inc.","displaySize":"","headline":null,"caption":"BridgeBio Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":134,"url":"https://media.zenfs.com/en/globenewswire.com/95609e0a840873fa0736db3ba42e9949"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iq7DUj1HEdREiIfZ9M6K3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/95609e0a840873fa0736db3ba42e9949","width":300,"height":134}},"lazy":false},{"type":"text","content":"- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $362.4 million, respectively","length":130,"tagName":"p"},{"type":"text","content":"- Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by differentiated clinical data and growing real-world confidence","length":271,"tagName":"p"},{"type":"text","content":"- New TTR amyloid depleter antibody program announced to explore the potential of ATTR-CM disease reversal; program expected to advance into the clinic between 2027 – 2028","length":171,"tagName":"p"},{"type":"text","content":"- The interim analysis from FORTIFY, BridgeBio’s Phase 3 study of BBP-418 in LGMD2I/R9, demonstrated broad benefit in all subgroups across α-controlled endpoints and a highly clinically meaningful and statistically significant 2.6 point benefit on NSAD relative to placebo at 12 months; based on these data, the FDA recommended orienting NDA toward traditional full approval; the Company intends to submit an NDA in first half of 2026","length":434,"tagName":"p"},{"type":"text","content":"- Rapid increase in diagnosis of ADH1 with >1,700 unique patients identified since October 2023; BridgeBio intends to submit an NDA to the FDA based on results from CALIBRATE, the Company’s Phase 3 clinical trial of encaleret, in the first half of 2026","length":255,"tagName":"p"},{"type":"text","content":"- Initiation of RECLAIM-HP, phase 3 trial of encaleret in chronic hypoparathyroidism, in summer 2026 subsequent to a recently completed End of Phase 2 interaction with FDA","length":171,"tagName":"p"},{"type":"text","content":"- LPLV achieved for PROPEL 3, the registrational Phase 3 study of ...